Key result
Carriers of ADAR1 polymorphisms, such as the rs2229857_T allele, had significantly lower odds of advanced liver fibrosis (aOR 0.43) compared to non-carriers in HIV/HCV-coinfected patients.
Why the study?
Do ADAR1 polymorphisms protect against severe liver disease in HIV/HCV-coinfected patients?
Cross-Sectional (n=220)
Do ADAR1 polymorphisms protect against severe liver disease in HIV/HCV-coinfected patients?
Odds Ratio: 0.43 (95% CI 0.22–0.82)
p-value: p=0.011
ADAR1 polymorphisms are associated with protection against severe liver disease in HIV/HCV-coinfected patients, which could inform therapeutic decision-making.
Should not yet inform management; leaves open whether ADAR1 variants modify fibrosis risk in coinfected patients.
The adenosine deaminase acting on RNA (ADAR1) gene is an interferon-stimulated gene involved in liver injury protection. Our aim was to analyze the association of polymorphisms within this gene with the severity of liver disease in European HIV/HCV-coinfected patients. We performed a cross-sectional study in 220 patients that underwent a liver biopsy. Five SNPs in the ADAR1 gene (rs1127326, rs1127317, rs1127314, rs1127313, rs2229857) were genotyped by GoldenGate assay. The outcome variables were fibrosis stage and necroinflammatory activity grade by METAVIR-score, aspartate aminotransferase to platelet ratio index (APRI), FIB-4 index, and fibrosis progression rate (FPR). In multivariate analysis, fibrosis progression rate (FPR) (aAMRs = 0.97) decreased in a dose-dependent manner with the presence of rs2229857_T, rs1127313_G, rs1127314_G and rs1127317_G; while rs1127326_T allele had only significant associations with FIB-4 (aAMRs ≤ 0.63) and FPR (aAMRs ≤ 0.97). Moreover, carriers of rs2229857_T, rs1127314_G, rs1127317_G, and rs1127326_T alleles were protected against advanced fibrosis (F ≥ 3) (adjusted ORs (aORs) ≤ 0.44), APRI ≥ 1.5 (aORs ≤ 0.33), and FPR ≥ 0.075 (aORs ≤ 0.45). rs1127313_G carriers showed lower odds of having F ≥ 3 (aORs = 0.39), FIB4 ≥ 3.25 (aOR = 0.22) and FPR ≥ 0.075 (aORs = 0.44). In conclusion, ADAR1 polymorphisms protected against severe liver disease in HIV/HCV-coinfected patients. These results could be used to improve therapeutic decision-making in clinical practice.
No takes yet. Share an insight, caveat, or question.
Medrano et al. (2017) conducted a cross-sectional in HIV/HCV-coinfection (n=220). ADAR1 polymorphisms (e.g., rs2229857_T allele) vs. Non-carriers / alternative alleles was evaluated on Advanced liver fibrosis (F ≥ 3) (aOR 0.43, 95% CI 0.22-0.82, p=0.011). Carriers of ADAR1 polymorphisms, such as the rs2229857_T allele, had significantly lower odds of advanced liver fibrosis (aOR 0.43) compared to non-carriers in HIV/HCV-coinfected patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: